U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Diaceutics PLC, (AIM: DXRX), today announces the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and ...
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...
CHICAGO (Reuters) - Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumours, but ...
Common Metabolic Enzyme Could Predict Cancer Immunotherapy Benefits — and Help More Patients Respond
A Rutgers Cancer Institute study in Cell Reports Medicine promises help with both those problems. It identifies a protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results